ECM
ALNY icon

ExodusPoint Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

ExodusPoint Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,823
Closed -$14.1M – 1501
2025
Q3 		$14.1M Buy
+30,823
New +$12.6M 0.14% 131
2024
Q4 		– Sell
-18,988
Closed -$5.22M – 1473
2024
Q3 		$5.22M Buy
+18,988
New +$4.94M 0.03% 410
2024
Q2 		– Sell
-18,658
Closed -$2.79M – 1488
2024
Q1 		$2.79M Buy
+18,658
New +$3.11M 0.02% 584
2023
Q2 		– Sell
-13,953
Closed -$2.79M – 1822
2023
Q1 		$2.79M Buy
+13,953
New +$2.93M 0.02% 747
2022
Q4 		– Sell
-3,122
Closed -$625K – 1606
2022
Q3 		$625K Sell
3,122
-7,541
-71% -$1.44M 0.01% 1287
2022
Q2 		$1.55M Buy
+10,663
New +$1.51M 0.02% 895
2022
Q1 		– Sell
-5,745
Closed -$974K – 2152
2021
Q4 		$974K Buy
+5,745
New +$1.07M 0.01% 1085
2021
Q3 		– Sell
-23,458
Closed -$3.98M – 2063
2021
Q2 		$3.98M Buy
23,458
+696
+3% +$102K 0.04% 435
2021
Q1 		$3.21M Buy
22,762
+19,661
+634% +$2.96M 0.05% 403
2020
Q4 		$403K Buy
+3,101
New +$414K ﹤0.01% 1378
2020
Q1 		– Sell
-23,876
Closed -$2.75M – 1053
2019
Q4 		$2.75M Buy
+23,876
New +$2.38M 0.05% 268

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

ExodusPoint Capital Management's ALNY Position: Q4 2025 in Review

ExodusPoint Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 30,823 shares — an estimated $14.1M sold.

ExodusPoint Capital Management first reported a position in ALNY in Q4 2019 and held it in 11 quarters. The position peaked at $14.1M in Q3 2025. 848 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • ExodusPoint Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • ExodusPoint Capital Management sold 30,823 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $14.1M.
  • ExodusPoint Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2019 and held it in 11 quarters.
  • ExodusPoint Capital Management's Alnylam Pharmaceuticals position peaked at $14.1M in Q3 2025.
  • 848 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.